Sartorius Stedim Biotech (DIM.PA)
Sartorius Stedim Biotech reported revenue of 3B EUR for the year ending 31 December 2025, up 6.7% from 2.8B a year earlier.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in EUR.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in EUR.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
2025 · ending 31 December 2025 |
3B |
+6.7% |
| Gross Profit |
2025 · ending 31 December 2025 |
1.3B |
+11.5% |
| Operating Income |
2025 · ending 31 December 2025 |
525.7M |
+41.9% |
| Net Income |
2025 · ending 31 December 2025 |
266M |
+49.0% |
| Cost of Revenue |
2025 · ending 31 December 2025 |
1.6B |
+3.1% |
| Operating Cash Flow |
2025 · ending 31 December 2025 |
692.2M |
-15.1% |
| EPS |
2025 · ending 31 December 2025 |
2.73 |
+50.8% |
Revenue and profit by financial year
As filed, in EUR. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
3B | 525.7M | 266M | — |
|---|
| 2024 | 2024-12-31 |
2.8B | 370.6M | 178.5M | — |
|---|
| 2023 | 2023-12-31 |
2.8B | 449.5M | 312.7M | — |
|---|
| 2022 | 2022-12-31 |
3.5B | 995.2M | 879.9M | — |
|---|
| 2021 | 2021-12-31 |
2.9B | 865.4M | 414.3M | — |
|---|
| 2020 | 2020-12-31 |
1.9B | 471.7M | 338.6M | — |
|---|
Every period
Revenue Annual
| Period | Ending | Revenue |
|---|
| FY25 | 2025-12-31 | 3B |
|---|
| FY24 | 2024-12-31 | 2.8B |
|---|
| FY23 | 2023-12-31 | 2.8B |
|---|
| FY22 | 2022-12-31 | 3.5B |
|---|
| FY21 | 2021-12-31 | 2.9B |
|---|
Gross Profit Annual
| Period | Ending | Gross Profit |
|---|
| FY25 | 2025-12-31 | 1.3B |
|---|
| FY24 | 2024-12-31 | 1.2B |
|---|
| FY23 | 2023-12-31 | 1.2B |
|---|
| FY22 | 2022-12-31 | 1.8B |
|---|
| FY21 | 2021-12-31 | 1.6B |
|---|
Operating Income Annual
| Period | Ending | Operating Income |
|---|
| FY25 | 2025-12-31 | 525.7M |
|---|
| FY24 | 2024-12-31 | 370.6M |
|---|
| FY23 | 2023-12-31 | 449.5M |
|---|
| FY22 | 2022-12-31 | 995.2M |
|---|
| FY21 | 2021-12-31 | 865.4M |
|---|
Net Income Annual
| Period | Ending | Net Income |
|---|
| FY25 | 2025-12-31 | 266M |
|---|
| FY24 | 2024-12-31 | 178.5M |
|---|
| FY23 | 2023-12-31 | 312.7M |
|---|
| FY22 | 2022-12-31 | 879.9M |
|---|
| FY21 | 2021-12-31 | 414.3M |
|---|
Cost of Revenue Annual
| Period | Ending | Cost of Revenue |
|---|
| FY25 | 2025-12-31 | 1.6B |
|---|
| FY24 | 2024-12-31 | 1.6B |
|---|
| FY23 | 2023-12-31 | 1.5B |
|---|
| FY22 | 2022-12-31 | 1.7B |
|---|
| FY21 | 2021-12-31 | 1.3B |
|---|
Operating Cash Flow Annual
| Period | Ending | Operating Cash Flow |
|---|
| FY25 | 2025-12-31 | 692.2M |
|---|
| FY24 | 2024-12-31 | 815.1M |
|---|
| FY23 | 2023-12-31 | 746.4M |
|---|
| FY22 | 2022-12-31 | 612.3M |
|---|
| FY21 | 2021-12-31 | 701.9M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | 2.73 |
|---|
| FY24 | 2024-12-31 | 1.81 |
|---|
| FY23 | 2023-12-31 | 3.37 |
|---|
| FY22 | 2022-12-31 | 9.51 |
|---|
| FY21 | 2021-12-31 | 4.50 |
|---|